RBC Capital analyst Nik Modi maintained a Hold rating on Colgate-Palmolive (CL – Research Report) yesterday and set a price target of $88.00. The company’s shares closed yesterday at $86.52.
Modi covers the Consumer Defensive sector, focusing on stocks such as Colgate-Palmolive, Clorox, and Constellation Brands. According to TipRanks, Modi has an average return of 6.4% and a 61.08% success rate on recommended stocks.
In addition to RBC Capital, Colgate-Palmolive also received a Hold from Wells Fargo’s Christopher Carey in a report issued on February 26. However, today, Goldman Sachs initiated coverage with a Buy rating on Colgate-Palmolive (NYSE: CL).
See today’s best-performing stocks on TipRanks >>
Based on Colgate-Palmolive’s latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of $4.95 billion and a net profit of $718 million. In comparison, last year the company earned a revenue of $4.63 billion and had a net profit of $5 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Colgate-Palmolive (CL) Company Description:
Colgate-Palmolive Company is a multinational consumer products name engaged in production and distribution of household, personal care, oral care, health care, and veterinary products. The company sells its products across more than 200 countries and territories. The company’s well known global brands include Colgate, Palmolive, Speed Stick, Lady Speed Stick, Ajax, Softsoap and Hill’s pet Nutrition. It has two operating business segment – Oral, Personal and Home Care, and Pet Nutrition.
Read More on CL:
- Colgate-Palmolive price target raised to $95 from $91 at Raymond James
- Colgate-Palmolive Welcomes Brian Newman to Board of Directors
- Colgate-Palmolive price target raised to $97 from $88 at Argus
- Colgate-Palmolive price target raised to $96 from $85 at Bernstein
- Colgate-Palmolive price target raised to $93 from $85 at Morgan Stanley
